{"id":145655,"date":"2025-04-23T07:00:00","date_gmt":"2025-04-23T05:00:00","guid":{"rendered":"https:\/\/www.startupbusiness.it\/claris-venture-first-closing-of-second-biotech-fund\/145655\/"},"modified":"2025-04-23T09:28:06","modified_gmt":"2025-04-23T07:28:06","slug":"claris-venture-first-closing-of-second-biotech-fund","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/","title":{"rendered":"Claris Venture, first closing of second biotech fund"},"content":{"rendered":"\n

Claris Ventures announces the first closing of Claris Biotech II, a venture capital fund dedicated to early-stage investments in biotech start-ups originating from the Italian research network, with a target fund size of EUR 100 million.<\/strong> The fund continues the path started with the first fund launched in 2020, which had raised a total of EUR 85 million and financed 10 biotech companies, active in therapeutic areas such as oncology, neurology, cardio-metabolic and rare diseases.<\/p>\n\n

Four therapeutic programmes supported by the first fund have already entered the clinical phase and the investee companies have raised a total of more than EUR 170 million in capital, attracting the interest of international investors and pharmaceutical groups, including Sanofi, Bristol Myers Squibb and ONO Pharmaceutical.<\/strong><\/p>\n\n

“Biotech represents an extraordinary opportunity for Italy, where there is scientific research of excellence, but still too often disconnected from industrial development paths. With Claris, we have introduced a way of working that starts from science and aggregates around it entrepreneurial skills, international investors and a path towards the clinic. We believe that this approach can make a concrete contribution to the maturation of the national ecosystem, bringing research and real impact closer together,’ Pietro Puglisi and Ciro Spedaliere, managing partners of Claris Ventures (pictured here with the team), tell Startupbusiness.<\/strong> <\/p>\n\n

‘This second fund marks an important step in our vision of growth and maturation of the biotech industry in Italy, starting from science and accompanying it towards clinical validation,’ Puglisi and Spedaliere added in a note<\/strong>. ‘<\/strong>We will continue to invest in new entrepreneurial realities born from high-impact discoveries: we are not afraid to take the first step and it is the only way to make a real contribution to the Italian biotech ecosystem, as well as an important opportunity for return.<\/p>\n\n

Claris Biotech II retains the focused approach of the first fund: selective investments in therapeutic programmes with a strong scientific rationale, associated with a deep clinical need and a consequent high potential. The objective is to accompany start-ups through to initial clinical validation, creating the conditions for partnering and mergers and acquisitions by large pharmaceutical groups. <\/p>\n\n

Among the institutional investors that have already joined the new fund are CDP Venture Capital and the European Investment Fund (EIF, part of the EIB Group), which confirm their commitment to supporting innovation in the lifesciences field in continuity with the support given to the first Claris Ventures fund.<\/p>\n\n

“As the leading venture capitalist in Europe, investing in innovative life science companies is one of our strategic priorities for the EIF,” comments Marco Marrone, chief investment officer of the EIF. <\/strong>“With our investment in Claris Biotech II, we aim to support new biotech companies born from excellent scientific discoveries, generating positive value for society and patients in Italy and Europe.<\/p>\n\n

Simona Corno, senior partner and co-head of CDP Venture Capital’s FoF VenturItaly II, adds: “We renew our support for Claris Ventures, an established Italian fund manager, which with Claris Biotech I has demonstrated its scouting capabilities and rapid construction of a portfolio of Italian biotech start-ups that are already characterised by growth and clear value creation. <\/strong>For CDP Venture Capital, the life sciences sector is a priority, and the subscription of Claris Biotech II, a follow-on fund that will support the growth of early-stage biotech also through collaborations at the international level, goes in this direction”. <\/p>\n\n

On the occasion of the first closing, Claris Ventures also announces that Giulia Vestri has joined the team as a partner<\/strong>. With a consolidated experience in biotech business development and pharmaceutical development, Vestri further enriches the team’s expertise, helping to strengthen the ability to support investees in the most critical phases of their growth path, from strategic ideation to the creation of industrial and clinical value.<\/p>\n\n

Claris Ventures will continue to work closely with the early-stage ecosystem, integrating scientific, industrial and financial expertise to accelerate the research transition to new drug development.<\/p>\n","protected":false},"excerpt":{"rendered":"

First closing of the new fund of the investment vehicle specialised in early-stage biotech start-ups<\/p>\n","protected":false},"author":125,"featured_media":145617,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1142],"tags":[1350,1143,1137,1136,1145],"companies":[2646],"journalist":[1518],"class_list":["post-145655","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-vc-voice","tag-biotech-en","tag-investments","tag-italy-en","tag-startup-en-2","tag-venture-capital-en-2","companies-claris-venture-en","journalist-editorial-staff-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp","width":150,"height":100,"crop":false,"srcset":false,"alt":"startup biotech"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp","width":1024,"height":683,"crop":false,"srcset":false,"alt":"startup biotech"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp","width":1280,"height":854,"crop":false,"srcset":false,"alt":"startup biotech"}},"acf":[],"yoast_head":"\nClaris Venture, first closing of second biotech fund<\/title>\n<meta name=\"description\" content=\"First closing of the new fund of the investment vehicle specialised in early-stage biotech start-ups\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Claris Venture, first closing of second biotech fund\" \/>\n<meta property=\"og:description\" content=\"First closing of the new fund of the investment vehicle specialised in early-stage biotech start-ups\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T05:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T07:28:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"Claris Venture, first closing of second biotech fund\",\"datePublished\":\"2025-04-23T05:00:00+00:00\",\"dateModified\":\"2025-04-23T07:28:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/\"},\"wordCount\":654,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Claris-Ventures-Team-2.webp\",\"keywords\":[\"biotech\",\"investments\",\"italy\",\"startup\",\"venture capital\"],\"articleSection\":[\"Vc Voice\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/\",\"name\":\"Claris Venture, first closing of second biotech fund\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Claris-Ventures-Team-2.webp\",\"datePublished\":\"2025-04-23T05:00:00+00:00\",\"dateModified\":\"2025-04-23T07:28:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"First closing of the new fund of the investment vehicle specialised in early-stage biotech start-ups\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/claris-venture-first-closing-of-second-biotech-fund\\\/145655\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Claris-Ventures-Team-2.webp\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Claris-Ventures-Team-2.webp\",\"width\":1280,\"height\":854,\"caption\":\"startup biotech\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Claris Venture, first closing of second biotech fund","description":"First closing of the new fund of the investment vehicle specialised in early-stage biotech start-ups","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/","og_locale":"en_US","og_type":"article","og_title":"Claris Venture, first closing of second biotech fund","og_description":"First closing of the new fund of the investment vehicle specialised in early-stage biotech start-ups","og_url":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/","og_site_name":"Startupbusiness.it","article_published_time":"2025-04-23T05:00:00+00:00","article_modified_time":"2025-04-23T07:28:06+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp","type":"image\/webp"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"Claris Venture, first closing of second biotech fund","datePublished":"2025-04-23T05:00:00+00:00","dateModified":"2025-04-23T07:28:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/"},"wordCount":654,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp","keywords":["biotech","investments","italy","startup","venture capital"],"articleSection":["Vc Voice"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/","url":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/","name":"Claris Venture, first closing of second biotech fund","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp","datePublished":"2025-04-23T05:00:00+00:00","dateModified":"2025-04-23T07:28:06+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"First closing of the new fund of the investment vehicle specialised in early-stage biotech start-ups","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/claris-venture-first-closing-of-second-biotech-fund\/145655\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/04\/Claris-Ventures-Team-2.webp","width":1280,"height":854,"caption":"startup biotech"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Vc Voice"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/145655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=145655"}],"version-history":[{"count":1,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/145655\/revisions"}],"predecessor-version":[{"id":145656,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/145655\/revisions\/145656"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/145617"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=145655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=145655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=145655"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=145655"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=145655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}